DGIdb - FCGR2A Gene Record

FCGR2A 2212 Druggable Genome

Alternate Names:

2212
FC FRAGMENT OF IGG RECEPTOR IIA
FCGR2A
CD32
CD32A
CDw32
FCG2
FCGR2
FCGR2A1
FcGR
IGFR2
146790
3616
ENSG00000143226
OTTHUMG00000034469
PA28063
Immunoglobulin gamma Fc receptor IIA
T22212
FC GAMMA RECEPTOR IIA
FcgammaRIIa

Gene Info:

Gene Biotype	PROTEIN_CODING

(1 More Sources)

Gene Categories: Category Details

DRUGGABLE GENOME

Publications:

Mendrinou E et al., 2017, FCGR3A-V158F polymorphism is a disease-specific pharmacogenetic marker for the treatment of psoriasis with Fc-containing TNFα inhibitors., Pharmacogenomics J
Dávila-Fajardo CL et al., 2015, FcGR genetic polymorphisms and the response to adalimumab in patients with rheumatoid arthritis., Pharmacogenomics
Montes A et al., 2014, Association of FCGR2A with the response to infliximab treatment of patients with rheumatoid arthritis., Pharmacogenet Genomics
Julià M et al., 2013, The role of Fcγ receptor polymorphisms in the response to anti–tumor necrosis factor therapy in psoriasis A pharmacogenetic study., JAMA Dermatol
Zhang et al., 2007, FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab., J. Clin. Oncol.
Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
Shepshelovich D et al., 2018, Fc-gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer., Cancer Med
Magnes T et al., 2018, The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab., Pharmacogenomics J
Morgen EK et al., 2017, Germline polymorphisms as biomarkers of tumor response in colorectal cancer patients treated with anti-EGFR monoclonal antibodies: a systematic review and meta-analysis., Pharmacogenomics J
Negri FV et al., 2014, Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy., Pharmacogenomics J
Jiménez Morales A et al., 2019, FCGR2A/FCGR3A Gene Polymorphisms and Clinical Variables as Predictors of Response to Tocilizumab and Rituximab in Patients With Rheumatoid Arthritis., J Clin Pharmacol
Hatjiharissi et al., 2007, Genetic linkage of Fc gamma RIIa and Fc gamma RIIIa and implications for their use in predicting clinical responses to CD20-directed monoclonal antibody therapy., Clin Lymphoma Myeloma
Kim et al., 2006, FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma., Blood
Criswell et al., 2004, The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept., Arthritis Rheum.
Hughes et al., 2004, Genetic risk factors for infection in patients with early rheumatoid arthritis., Genes Immun.
Hofmann HP et al., 2016, Characterization and non-clinical assessment of the proposed etanercept biosimilar GP2015 with originator etanercept (Enbrel(®))., Expert Opin Biol Ther
Arora T et al., 2009, Differences in binding and effector functions between classes of TNF antagonists., Cytokine
Tamura K et al., 2011, FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer., Ann Oncol
Musolino A et al., 2008, Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer., J Clin Oncol

ADALIMUMAB FCGR2A

Interaction Score: 3.64

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27044681 25823785 24667440 24048425 17016423 17139284

Sources:
PharmGKB
ETANERCEPT FCGR2A

Interaction Score: 3.25

Interaction Types & Directionality:

ligand

Interaction Info:

PMIDs:
27044681 24048425 15457442 15526004 27463856 19128982

Sources:
PharmGKB
VALZIFLOCEPT FCGR2A

Interaction Score: 2.94

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
TRASTUZUMAB FCGR2A

Interaction Score: 2.52

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21109570 18347005 17704420 17016423 17139284

Sources:
PharmGKB
RITUXIMAB FCGR2A

Interaction Score: 2.52

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
30457672 17324336 16609067

Sources:
PharmGKB
INFLIXIMAB FCGR2A

Interaction Score: 2.21

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27044681 25823785 24667440 24048425

Sources:
PharmGKB
CETUXIMAB FCGR2A

Interaction Score: 1.64

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17704420 17016423 17139284 30318772 28719596 27897268 23296156

Sources:
PharmGKB

Ensembl: ENSG00000143226
- Version: 101_38
Alternate Names:

FCGR2A Ensembl Gene Name

Gene Info:

Gene Biotype PROTEIN_CODING

Publications:

PharmGKB: FCGR2A

Version: 18-August-2020

Alternate Names:

PA28063 PharmGKB ID

Gene Info:

Publications:

Musolino A et al., 2008, Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer., J Clin Oncol

Tamura K et al., 2011, FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer., Ann Oncol

Jiménez Morales A et al., 2019, FCGR2A/FCGR3A Gene Polymorphisms and Clinical Variables as Predictors of Response to Tocilizumab and Rituximab in Patients With Rheumatoid Arthritis., J Clin Pharmacol

HingoraniCasas: ENSG00000143226
- Version: 31-May-2017
Alternate Names:

ENSG00000143226 Gene Symbol

FCGR2A Ensembl Id

Gene Info:

Gene Categories:

DRUGGABLE GENOME

Publications:
Tempus: FCGR2A
- Version: 11-November-2018
Alternate Names:

FCGR2A Gene Symbol

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
TTD: Immunoglobulin gamma Fc receptor IIA
- Version: 2020.06.01
Alternate Names:

FCGR2A TTD Gene Abbreviation

T22212 TTD Target ID

Gene Info:

Publications:

FCGR2A	TTD Gene Abbreviation
T22212	TTD Target ID

FCGR2A Gene Record

FCGR2A 2212 Druggable Genome

Alternate Names:

Gene Info:

Gene Categories: Category Details

Publications:

ADALIMUMAB FCGR2A

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27044681 25823785 24667440 24048425 17016423 17139284

Sources: PharmGKB

ETANERCEPT FCGR2A

Interaction Types & Directionality: ligand

Interaction Info:

PMIDs: 27044681 24048425 15457442 15526004 27463856 19128982

Sources: PharmGKB

VALZIFLOCEPT FCGR2A

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: TTD

TRASTUZUMAB FCGR2A

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 21109570 18347005 17704420 17016423 17139284

Sources: PharmGKB

RITUXIMAB FCGR2A

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 30457672 17324336 16609067

Sources: PharmGKB

INFLIXIMAB FCGR2A

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27044681 25823785 24667440 24048425

Sources: PharmGKB

CETUXIMAB FCGR2A

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17704420 17016423 17139284 30318772 28719596 27897268 23296156

Sources: PharmGKB

Ensembl: ENSG00000143226

Alternate Names: FCGR2A Ensembl Gene Name

Gene Info: Gene Biotype PROTEIN_CODING

Publications:

PharmGKB: FCGR2A

Alternate Names: PA28063 PharmGKB ID

Gene Info:

HingoraniCasas: ENSG00000143226

Alternate Names: ENSG00000143226 Gene Symbol FCGR2A Ensembl Id

Gene Info:

Gene Categories: DRUGGABLE GENOME

Publications:

Tempus: FCGR2A

Alternate Names: FCGR2A Gene Symbol

Gene Info:

Gene Categories: CLINICALLY ACTIONABLE

Publications:

TTD: Immunoglobulin gamma Fc receptor IIA

Alternate Names: FCGR2A TTD Gene Abbreviation T22212 TTD Target ID

Gene Info:

Publications:

Interaction Types & Directionality:

n/a

PMIDs:
27044681 25823785 24667440 24048425 17016423 17139284

Sources:
PharmGKB

Interaction Types & Directionality:

ligand

PMIDs:
27044681 24048425 15457442 15526004 27463856 19128982

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TTD

Interaction Types & Directionality:

n/a

PMIDs:
21109570 18347005 17704420 17016423 17139284

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
30457672 17324336 16609067

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
27044681 25823785 24667440 24048425

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
17704420 17016423 17139284 30318772 28719596 27897268 23296156

Sources:
PharmGKB

Alternate Names:

FCGR2A Ensembl Gene Name

Gene Info:

Gene Biotype PROTEIN_CODING

Alternate Names:

PA28063 PharmGKB ID

Alternate Names:

ENSG00000143226 Gene Symbol

FCGR2A Ensembl Id

Gene Categories:

DRUGGABLE GENOME

Alternate Names:

FCGR2A Gene Symbol

Gene Categories:

CLINICALLY ACTIONABLE

Alternate Names:

FCGR2A TTD Gene Abbreviation

T22212 TTD Target ID